Highlights

• More and more triple-negative patients are getting pre-operative therapy, because there is some evidence that we can tailor therapy based on how well the tumor responds in the breast.
• I think probably only about half [of patients who should be BRCA-tested are actually getting tested], either they miss the family history or it does not get done, or there is not good insurance coverage, or the patient has concerns about genetic testing, or they are waiting to see a genetic counselor. So, there are a lot of obstacles, it is getting better, it will continue to get better, but currently it is nowhere near where it should be in terms of who is getting tested.
• Lynparza was approved earlier, so people got used to prescribing it, it was used by our colleagues in ovarian for years before that, and so, I – like most people, I am more accustomed to prescribing Lynparza, so typically that is what I prescribe unless there is some insurance, or other reason not to. So, the majority of my patients, 80%, are going to get Lynparza.